REG - ValiRx PLC - Appointment of Director

ValiRxAnnouncement

29/06/2020 11:45

RNS Number : 3917R
  
ValiRx PLC
  
29 June 2020
  
 

VALIRX PLC
("ValiRx", the "Company" or the "Group")
 
Appointment of Director
 
London, UK, 29 June 2020: ValiRx (AIM:VAL) announces that, further to the announcement of 27 May 2020, Kevin Cox has been appointed as Non-executive Chairman of the Company with effect from 26 June 2020.
 
The following information is disclosed in respect of Dr Kevin Paul Cox (age 61) pursuant to Schedule 2(g) of the AIM Rules for Companies:



Current directorships and partnerships


Directorships and partnerships held in the past five years




Aurora CBT Limited


Bioindustry Association




Biotaspheric Limited


Imanova Limited




Biorelate Limited


Perenna Consulting Limited




British Neuroscience Association Limited








The Griffin Practice Limited







 
Mr Kevin Cox does not hold any ordinary shares nor options over ordinary shares in the Company.
 
There is no further information which is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of Mr Kevin Cox.
 
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
*** ENDS ***
 
For more information, please contact:
 



ValiRx plc


Tel: +44 (0) 20 7073 2628
www.valirx.com




Suzanne Dilly


Suzanne.Dilly@valirx.com




Cairn Financial Advisers LLP (Nominated Adviser) 
Liam Murray / Jo Turner / Ludovico Lazzaretti


Tel: +44 (0) 20 7213 0880




Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker 


Tel: +44 (0) 20 7469 0930



 
 
Notes for Editors
 
About ValiRx 
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer.
 
The Company's business model focuses on identifying and in-licensing early stage projects, adding value through scientific development and then out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the Company reduces risk while increasing the potential for realising value. 
 
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. 
 
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
BOAFLFSIRFIAFII